La Clinica terapeutica · 2026
Comprehensive Evaluation of Coronary Pathophysiology in the Context of COVID-19: Clinical Insights and Angiographic Assessment.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abohamr Samah I, Abazid Rami M, Aloui Hatem M, Aldossari Mubarak A, Musa Yagoub, Abdelhamid Ahmed W, Afkham Mohammad, Alhussini Ayman Uthman, Abdelhamid Sara W, Rabie Ahmed A, Elkilany Galal, Singh Ram B, AlHussaini Khalid I, Aldali Jehad A, Qutob Rayan A, Elsheikh Eman
Аннотация
BACKGROUND: The COVID-19 pandemic has severely impacted cardiology, with myocardial injury and new-onset cardiac dysfunction observed even without respiratory symptoms. The Aim of the study aimed to evaluate angiographic and clinical characteristics of COVID-19-positive patients who were presented with acute coronary syndrome.
METHOD: This retrospective case-control study involved 80 COVID-19-positive patients with acute coronary syndrome who underwent angiography, compared to matched COVID-19-negative controls. Conducted at King Saud Medical City, Riyadh, between June 2021 and July 2022. It included angiographic, echocardiographic and laboratory evaluations.
RESULTS: 80 (1.6%) of 5134 COVID-19 patients underwent coronary angiography for coronary artery disease over 14 months. The COVID-19-positive and control groups were primarily male (78.75% vs. 75%) and had similar mean ages (57.1±10.86 vs. 55.93±10 years). The control group had higher rates of diabetes (81.3% vs. 66.3%) and hypertension (85% vs. 57.5%), while the COVID-19 group had higher smoking rates, STEMI (50% vs. 26.3%), and elevated D-dimer, C reactive protein (CRP), and cardiac troponins. COVID-19 patients had more ventricular thrombus (15% vs. 3.75%), RV dilation (36.25% vs. 11.25%), and pulmonary hypertension (50% vs. 26.3%). COVID-19 patients had more single-vessel disease (35% vs. 17.5%), and controls had more three-vessel disease (47.5% vs 22.5%). The COVID-19 group also used more thrombus aspiration (17.5% vs. 5%) and glycoprotein IIb/IIIa inhibitors (37.5% vs. 6.33%).
CONCLUSIONS: The findings of this study show that COVID-19 increases cardiovascular injury. Even if the cause is unknown, cardiac injury must be detected quickly. ACS, including STEMI, can kill if not diagnosed and treated immediately. All COVID-19-positive patients with chest pain should be treated with a high index of suspicion due to the risk of coronary thrombosis due to hypercoagulability.
METHOD: This retrospective case-control study involved 80 COVID-19-positive patients with acute coronary syndrome who underwent angiography, compared to matched COVID-19-negative controls. Conducted at King Saud Medical City, Riyadh, between June 2021 and July 2022. It included angiographic, echocardiographic and laboratory evaluations.
RESULTS: 80 (1.6%) of 5134 COVID-19 patients underwent coronary angiography for coronary artery disease over 14 months. The COVID-19-positive and control groups were primarily male (78.75% vs. 75%) and had similar mean ages (57.1±10.86 vs. 55.93±10 years). The control group had higher rates of diabetes (81.3% vs. 66.3%) and hypertension (85% vs. 57.5%), while the COVID-19 group had higher smoking rates, STEMI (50% vs. 26.3%), and elevated D-dimer, C reactive protein (CRP), and cardiac troponins. COVID-19 patients had more ventricular thrombus (15% vs. 3.75%), RV dilation (36.25% vs. 11.25%), and pulmonary hypertension (50% vs. 26.3%). COVID-19 patients had more single-vessel disease (35% vs. 17.5%), and controls had more three-vessel disease (47.5% vs 22.5%). The COVID-19 group also used more thrombus aspiration (17.5% vs. 5%) and glycoprotein IIb/IIIa inhibitors (37.5% vs. 6.33%).
CONCLUSIONS: The findings of this study show that COVID-19 increases cardiovascular injury. Even if the cause is unknown, cardiac injury must be detected quickly. ACS, including STEMI, can kill if not diagnosed and treated immediately. All COVID-19-positive patients with chest pain should be treated with a high index of suspicion due to the risk of coronary thrombosis due to hypercoagulability.